1. Home
  2. BBIO
  3. BBIO News

Latest BridgeBio Pharma Inc. (BBIO) News on October 9, 2025

BridgeBio Pharma (BBIO) Is Up 5.6% After Acoramidis Shows Broad ATTR-CM Benefit in Phase 3 Data
BBIO

Simply Wall St.

5 days ago

BridgeBio Pharma (BBIO) Is Up 5.6% After Acoramidis Shows Broad ATTR-CM Benefit in Phase 3 Data

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

5 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch
BBIO

Insider Monkey

6 days ago

UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch

BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics
BBIO

Insider Monkey

7 days ago

BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Sells Part of Beyonttra Royalty Rights for $300 Million

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
BBIO

GlobeNewswire

3 months ago

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Insider Sold Shares Worth $4,422,800, According to a Recent SEC Filing

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
BBIO

GlobeNewswire

3 months ago

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
BBIO

TipRanks

3 months ago

TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box

Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
BBIO

Insider Monkey

3 months ago

Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating
BBIO

Insider Monkey

4 months ago

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating

BBIO

MT Newswires

4 months ago

Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target

BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BBIO

Insider Monkey

4 months ago

BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright

BridgeBio price target raised to $42 from $37 at BMO Capital
BBIO

TipRanks

4 months ago

BridgeBio price target raised to $42 from $37 at BMO Capital

Exploring High Growth Tech Stocks In The US Market
BBIO

Simply Wall St.

4 months ago

Exploring High Growth Tech Stocks In The US Market

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
BBIO

GlobeNewswire

4 months ago

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors
BBIO

Barrons.com

5 months ago

Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment
BBIO

Insider Monkey

5 months ago

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment

Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
BBIO

Zacks

5 months ago

Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
BBIO

GlobeNewswire

5 months ago

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

BBIO

MT Newswires

5 months ago

BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
BBIO

GlobeNewswire

5 months ago

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug
BBIO

Clinical Trials Arena

5 months ago

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug

Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday
BBIO

Insider Monkey

5 months ago

Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday

Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
BBIO

Zacks

5 months ago

Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
BBIO

GlobeNewswire

5 months ago

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
BBIO

GlobeNewswire

5 months ago

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
BBIO

GlobeNewswire

5 months ago

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

BBIO

MT Newswires

5 months ago

Bridgebio Pharma Insider Sold Shares Worth $3,849,900, According to a Recent SEC Filing

BBIO

MT Newswires

5 months ago

Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating

High Growth Tech Stocks In The US Market May 2025
BBIO

Simply Wall St.

5 months ago

High Growth Tech Stocks In The US Market May 2025

BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations
BBIO

Simply Wall St.

5 months ago

BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday
BBIO

Insider Monkey

5 months ago

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday

BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations
BBIO

Investor's Business Daily

5 months ago

BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations

BBIO

Thomson Reuters StreetEvents

5 months ago

Q1 2025 BridgeBio Pharma Inc Earnings Call

BBIO

MT Newswires

5 months ago

UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating

BridgeBio sales of new heart drug outstrip expectations
BBIO

BioPharma Dive

5 months ago

BridgeBio sales of new heart drug outstrip expectations

BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
BBIO

GuruFocus.com

5 months ago

BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BBIO

Zacks

5 months ago

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

BBIO

MT Newswires

5 months ago

BridgeBio Pharma Q1 Loss Widens, Revenue Drops

BBIO

Associated Press Finance

5 months ago

BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
BBIO

Investor's Business Daily

5 months ago

BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
BBIO

GlobeNewswire

5 months ago

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential
BBIO

Insider Monkey

5 months ago

BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: What to Expect
BBIO

GuruFocus.com

5 months ago

BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: What to Expect

BBIO

MT Newswires

5 months ago

BridgeBio Pharma's Beyonttra Approved in UK for Heart Condition due to Amyloidosis

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
BBIO

GlobeNewswire

5 months ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BBIO

MT Newswires

5 months ago

Bridgebio Pharma Insider Sold Shares Worth $2,558,025, According to a Recent SEC Filing

Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth
BBIO

Zacks

6 months ago

Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
BBIO

GlobeNewswire

6 months ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO

MT Newswires

6 months ago

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
BBIO

GlobeNewswire

6 months ago

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

BBIO

MT Newswires

6 months ago

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy
BBIO

Insider Monkey

6 months ago

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy

BBIO

MT Newswires

6 months ago

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
BBIO

GlobeNewswire

6 months ago

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
BBIO

GlobeNewswire

6 months ago

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
BBIO

Investor's Business Daily

7 months ago

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
BBIO

Pharmaceutical Technology

7 months ago

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug

Alnylam Stock Jumps After the FDA Approves Its Heart Drug
BBIO

The Wall Street Journal

7 months ago

Alnylam Stock Jumps After the FDA Approves Its Heart Drug

Alnylam Heart Drug Approval Sets Up Challenge With Pfizer
BBIO

Bloomberg

7 months ago

Alnylam Heart Drug Approval Sets Up Challenge With Pfizer

BBIO

MT Newswires

7 months ago

UBS Adjusts Price Target on BridgeBio Pharma to $65 From $62, Maintains Buy Rating

BBIO

MT Newswires

7 months ago

BridgeBio Pharma Names New CFO

BridgeBio Announces CFO Succession
BBIO

GlobeNewswire

7 months ago

BridgeBio Announces CFO Succession

BBIO

MT Newswires

7 months ago

Sector Update: Health Care Stocks Retreat Thursday Afternoon

BBIO

MT Newswires

7 months ago

BridgeBio Shares Fall After KKR Genetic Disorder Sells 6 Million Shares

BridgeBio Oncology and Helix enter definitive merger agreement
BBIO

Pharmaceutical Technology

7 months ago

BridgeBio Oncology and Helix enter definitive merger agreement

BBIO

MT Newswires

7 months ago

Helix Acquisition to Merge With BridgeBio Oncology Therapeutics

BridgeBio oncology spinout to go public in blank-check merger
BBIO

BioPharma Dive

7 months ago

BridgeBio oncology spinout to go public in blank-check merger

BBIO

MT Newswires

7 months ago

Bridgebio Pharma Insider Sold Shares Worth $282,115, According to a Recent SEC Filing

BBIO

MT Newswires

7 months ago

Bridgebio Pharma Insider Sold Shares Worth $2,517,971, According to a Recent SEC Filing

BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts
BBIO

Insider Monkey

7 months ago

BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

BBIO

MT Newswires

7 months ago

BridgeBio Pharma Prices $500 Million Convertible Senior Notes Offering

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
BBIO

GlobeNewswire

7 months ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
BBIO

GlobeNewswire

7 months ago

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Why BridgeBio Pharma, Inc. (BBIO) is the Best Performing Pharma Stock So Far in 2025
BBIO

Insider Monkey

8 months ago

Why BridgeBio Pharma, Inc. (BBIO) is the Best Performing Pharma Stock So Far in 2025

BridgeBio price target raised to $52 from $49 at Scotiabank
BBIO

TipRanks

8 months ago

BridgeBio price target raised to $52 from $49 at Scotiabank

BBIO

Morningstar Research

8 months ago

Analyst Report: BridgeBio Pharma, Inc.

BBIO

MT Newswires

8 months ago

Cantor Fitzgerald Adjusts BridgeBio Pharma Price Target to $95 From $70, Maintains Overweight Rating

BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings
BBIO

GuruFocus.com

8 months ago

BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings

BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates
BBIO

Zacks

8 months ago

BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates

BBIO

MT Newswires

8 months ago

BridgeBio Pharma Q4 Loss Widens, Revenue Rises -- Shares Up Pre-Bell

BBIO

Associated Press Finance

8 months ago

BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
BBIO

GlobeNewswire

8 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BridgeBio’s heart drug launch gets off to a fast start
BBIO

BioPharma Dive

8 months ago

BridgeBio’s heart drug launch gets off to a fast start

BBIO

MT Newswires

8 months ago

BridgeBio Pharma Insider Sold Shares Worth $1,140,024, According to a Recent SEC Filing

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
BBIO

GlobeNewswire

8 months ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BridgeBio price target raised to $49 from $48 at Scotiabank
BBIO

TipRanks

8 months ago

BridgeBio price target raised to $49 from $48 at Scotiabank

EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment
BBIO

Pharmaceutical Technology

8 months ago

EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment

BBIO

MT Newswires

8 months ago

BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
BBIO

GlobeNewswire

8 months ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
BBIO

BioPharma Dive

8 months ago

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts
BBIO

Insider Monkey

8 months ago

Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts

DHT, Evolv Technologies, and More Stocks See Action From Activist Investors
BBIO

Barrons.com

8 months ago

DHT, Evolv Technologies, and More Stocks See Action From Activist Investors

Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday
BBIO

Insider Monkey

8 months ago

Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday

BBIO

MT Newswires

8 months ago

BridgeBio Pharma Insider Sold Shares Worth $2,467,761, According to a Recent SEC Filing

BBIO

MT Newswires

8 months ago

BridgeBio Pharma Insider Sold Shares Worth $21,788,650, According to a Recent SEC Filing

Share on Social Networks: